STUDY

Eucrisa came out ahead of Elidel and Protopic, but only in an indirect comparison

“Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis.” Thom H et al. Dermatology and Therapy. January 2022

Thom H et al. · Dermatology and Therapy · January 2022

Matching-adjusted indirect comparison
The finding

An indirect analysis estimated higher odds of clear or almost clear skin with crisaborole than with pimecrolimus 1% or tacrolimus 0.03%.

Type of study

Matching-adjusted indirect comparison

An indirect comparison across separate trials. The authors reweighted the crisaborole trial participants to make their measured characteristics more like participants in the comparator trials.
At a glance

Who was studied and for how long

Population
Ages 2 and up
Mild to moderate eczema
Compared
Separate trials
Crisaborole, pimecrolimus and tacrolimus
Outcome
Clear or almost clear
Investigator rating
What they did

How the study worked

Collect dataThe analysis used patient-level data from two crisaborole trials and published comparator trial results.
Reweight participantsThe authors matched measured characteristics across trials.
Estimate responseThey compared the odds of reaching clear or almost clear skin.
What they found

The results

Crisaborole vs pimecrolimus 1%

Estimated odds ratio for clear or almost clear skin was 2.03 (95% CI 1.45 to 2.85, p < 0.001).

Crisaborole vs tacrolimus 0.03%

The estimated odds ratio was 1.50 (95% CI 1.09 to 2.05, p = 0.012).

This analysis estimates relative odds from different trials. It could not compare safety and does not establish an advantage over tacrolimus 0.1%.
Who paid for it

Funding and conflicts of interest

Pfizer sponsored the analysis and funded writing support. Several authors were Pfizer employees or reported consulting fees from Pfizer.

How much to trust it

Strengths and limits

Strengths

  • Used individual data for the crisaborole group
  • Specified the outcome and strengths
  • Reported uncertainty around estimates

Limits

  • No shared comparable control
  • Unmeasured differences between trials can affect results
  • Effective sample size shrank after weighting
  • Safety outcomes could not be compared
Limited confidence. Without a shared control, the result depends on whether the analysis captured all important differences between trials.
What it means for you

The takeaway

Indirect evidence

The analysis favored crisaborole over two specific strengths on one skin rating. A head-to-head trial could give a different result.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

Odds ratio

A comparison of odds, which differs from a comparison of percentages.

Original source

Thom H, Cheng V, Keeney E, Neary MP, Eccleston A, Zang C, Cappelleri JC, Cha A, Thyssen JP. Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis.. Dermatol Ther (Heidelb). 2022;12(1):185-194.

PMID 34877623